Canada markets close in 1 hour 16 minutes
  • S&P/TSX

    19,444.45
    -111.70 (-0.57%)
     
  • S&P 500

    4,276.20
    +2.67 (+0.06%)
     
  • DOW

    33,573.91
    -44.97 (-0.13%)
     
  • CAD/USD

    0.7407
    +0.0009 (+0.12%)
     
  • CRUDE OIL

    93.85
    +3.46 (+3.83%)
     
  • Bitcoin CAD

    35,454.62
    +154.16 (+0.44%)
     
  • CMC Crypto 200

    562.65
    +0.00 (+0.00%)
     
  • GOLD FUTURES

    1,893.70
    -26.10 (-1.36%)
     
  • RUSSELL 2000

    1,775.19
    +13.58 (+0.77%)
     
  • 10-Yr Bond

    4.6320
    +0.0740 (+1.62%)
     
  • NASDAQ

    13,094.11
    +30.50 (+0.23%)
     
  • VOLATILITY

    18.86
    -0.08 (-0.42%)
     
  • FTSE

    7,593.22
    -32.50 (-0.43%)
     
  • NIKKEI 225

    32,371.90
    +56.85 (+0.18%)
     
  • CAD/EUR

    0.7046
    +0.0052 (+0.74%)
     

Stocks in play: PharmaTher Inc

Today submitted its meeting package with the U.S. Food and Drug Administration to discuss advancing KETARX™ into Phase 3 development as a treatment for levodopa-induced dyskinesia in Parkinson’s disease. This Type C meeting allows the Company to discuss with the FDA its plans for a Phase 3 clinical study to support the submission of a new drug application under the 505(b)(2) regulatory pathway for KETARX™ in treating LID-PD. In addition, the Company has requested guidance from the FDA to obtain Fast Track Designation for KETARX™. The Type C meeting is via written responses. The goal date for the FDA in providing its written responses is March 20, 2023. PharmaTher Inc shares C.PHRM are trading unchanged at $0.12.

Read: